CoChat

Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

Open access
Vincenti, Flavio, Blancho, Gilles, Durrbach, Antoine, Friend, Peter, Grinyo, Josep, Halloran, Philip F., Klempnauer, Jurgen, Lang, Philippe, Larsen, Christian P., Mühlbacher, Ferdinand, Nashan, Björn, Soulillou, Jean-Paul, Vanrenterghem, Yves, Wekerle, Thomas, Agarwal, Mamta, Gujrathi, Sheila, Shen, Jinshan, Shi, Rebecca, Townsend, Robert, Charpentier, Bernard · 2010 · Journal of the American Society of Nephrology
Cited by 189

The DOI matches its Crossref record.

Abstract

Belatacept is a first-in-class co-stimulation blocker in development for primary maintenance immunosuppression. A Phase II study comparing belatacept with cyclosporine (CsA) for prevention of acute rejection and protection of renal function in kidney transplant recipients demonstrated similar efficacy and significantly higher measured GFR at 1 year for belatacept, but the incidence of posttransplantation lymphoproliferative disorder was higher. Here, we present the results for the extension of this trial, which aimed to assess long-term safety and efficacy of belatacept. Seventy-eight of 102 patients who were receiving belatacept and the 16 of 26 who were receiving CsA completed the long-term extension period. GFR remained stable in patients who were receiving belatacept for 5 years, and the incidences of death/graft loss or acute rejection were low. The frequencies of serious infections were 16% for belatacept and 27% for CsA, and neoplasms occurred in 12% of each group. No patients who were treated with belatacept and one patient who was treated with CsA developed posttransplantation lymphoproliferative disorder during the follow-up period. Serious gastrointestinal disorders occurred more frequently with belatacept (12% belatacept versus 8% CsA), and serious cardiac disorders occurred more frequently with CsA (2% belatacept versus 12% CsA). Pharmacokinetic analyses showed consistent exposure to belatacept over time. CD86 receptor saturation was higher in patients who were receiving belatacept every 4 weeks (74%) compared with every 8 weeks (56%). In conclusion, this study demonstrated high patient persistence with intravenous belatacept, stable renal function, predictable pharmacokinetics, and good safety with belatacept over 5 years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2009111109

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 189

Metadata

Authors
Vincenti, F., Blancho, G., Durrbach, A., Friend, P., Grinyo, J., Halloran, P. F., Klempnauer, J., Lang, P., Larsen, C. P., Mühlbacher, F., Nashan, B., Soulillou, J.-P., Vanrenterghem, Y., Wekerle, T., Agarwal, M., Gujrathi, S., Shen, J., Shi, R., Townsend, R., & Charpentier, B.
Venue
Journal of the American Society of Nephrology
Published
2010-09
Volume
21
Issue
9
Pages
1587-1596
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2130168880
Cited by
189
References
0
FWCI
17.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Five-Year Safety and Efficacy of Belatacept in Renal Transplantation. https://app.cochat.ai/papers/10.1681/asn.2009111109
The paper
Vincenti, F., Blancho, G., Durrbach, A., Friend, P., Grinyo, J., Halloran, P. F., Klempnauer, J., Lang, P., Larsen, C. P., Mühlbacher, F., Nashan, B., Soulillou, J.-P., Vanrenterghem, Y., Wekerle, T., Agarwal, M., Gujrathi, S., Shen, J., Shi, R., Townsend, R., & Charpentier, B. (2010). Five-Year Safety and Efficacy of Belatacept in Renal Transplantation. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2009111109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.